Document Detail


The acute effects of HIV protease inhibitors on insulin suppression of glucose production in healthy HIV-negative men.
MedLine Citation:
PMID:  19680131     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: The effects of different HIV protease inhibitors (PIs) on peripheral insulin resistance have been described, but less is known about their effects on insulin suppression of endogenous glucose production (EGP).
METHODS: We tested the acute effects of 3 PIs, indinavir, ritonavir, and amprenavir, on EGP quantified by stable isotope techniques during the hyperinsulinemic, euglycemic clamp in 3 similar placebo-controlled protocols.
RESULTS: EGP was higher with indinavir in the hyperinsulinemic state than with placebo (4.1 +/- 1.3 vs. 2.2 +/- 0.8 microg x kg(-1) x min(-1), P = 0.04). A trend toward higher EGP was seen with ritonavir (3.6 +/- 0.3 vs. 3.0 +/- 0.5 microg x kg(-1) x min(-1), P = 0.08). There was no evidence that amprenavir blunted insulin suppression of EGP compared with placebo (2.9 +/- 0.04 vs. 3.2 +/- 0.7 microg x kg(-1) x min(-1), P = 0.63).
CONCLUSIONS: Some PIs can acutely blunt the ability of insulin to suppress EGP, but, as with insulin resistance, the effects of PIs on EGP are drug-specific, not class-specific.
Authors:
Grace A Lee; Jean-Marc Schwarz; Sophie Patzek; Seungki Kim; Artem Dyachenko; Michael Wen; Kathleen Mulligan; Morris Schambelan; Carl Grunfeld
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of acquired immune deficiency syndromes (1999)     Volume:  52     ISSN:  1944-7884     ISO Abbreviation:  J. Acquir. Immune Defic. Syndr.     Publication Date:  2009 Oct 
Date Detail:
Created Date:  2010-02-01     Completed Date:  2010-02-16     Revised Date:  2014-09-14    
Medline Journal Info:
Nlm Unique ID:  100892005     Medline TA:  J Acquir Immune Defic Syndr     Country:  United States    
Other Details:
Languages:  eng     Pagination:  246-8     Citation Subset:  IM; X    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Carbamates / adverse effects*
Glucose / metabolism*
HIV Protease Inhibitors / adverse effects*
Human Experimentation
Humans
Indinavir / adverse effects*
Insulin / metabolism*
Male
Placebos / administration & dosage
Ritonavir / adverse effects*
Sulfonamides / adverse effects*
Grant Support
ID/Acronym/Agency:
DK54615/DK/NIDDK NIH HHS; DK66999/DK/NIDDK NIH HHS; R01 DK066999/DK/NIDDK NIH HHS; R01 DK066999-01/DK/NIDDK NIH HHS; R01 DK066999-02/DK/NIDDK NIH HHS; R01 DK066999-03/DK/NIDDK NIH HHS; R01 DK066999-04/DK/NIDDK NIH HHS; R01 DK066999-05/DK/NIDDK NIH HHS; R01 DK066999-06/DK/NIDDK NIH HHS; R01 DK066999-07/DK/NIDDK NIH HHS; R01 DK066999-08/DK/NIDDK NIH HHS; RR00083/RR/NCRR NIH HHS
Chemical
Reg. No./Substance:
0/Carbamates; 0/HIV Protease Inhibitors; 0/Insulin; 0/Placebos; 0/Sulfonamides; 161814-49-9/amprenavir; 5W6YA9PKKH/Indinavir; IY9XDZ35W2/Glucose; O3J8G9O825/Ritonavir
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Computer simulator among experts involved in screening colonoscopy.
Next Document:  Transcatheter closure of coronary artery fistula using the new Amplatzer vascular plug and a telesco...